ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Bloom syndrome protein (BLM) is overexpressed in prostate cancer (PCa), correlating with poor patient prognosis.
• DNA repair inhibitors combined with DNA-damaging agents offer a promising strategy for enhanced cancer therapy.
• Targeting DNA repair mechanisms can overcome treatment resistance and improve therapeutic outcomes.

Purpose of the Study:

• To investigate the synergistic effect of ML216 (a BLM helicase inhibitor) and cisplatin (CDDP) in PCa cells.
• To elucidate the underlying molecular mechanisms of this combination therapy.
• To evaluate the potential of ML216 and CDDP as a novel anticancer tactic.

Main Methods:

• Cell viability assays to assess antiproliferative effects.
• Neutral comet assay and Western blotting (WB) to evaluate DNA damage and protein expression.
• Cell cycle and apoptosis analysis to determine treatment-induced cell death.
• Bioinformatic analysis of BLM expression in PCa patient data.

Main Results:

• ML216 combined with CDDP demonstrated significant antiproliferative activity across three PCa cell lines.
• The combination therapy increased DNA damage markers (γH2AX) and apoptosis (caspase-3 cleavage).
• ML216 reduced BLM expression, enhancing PCa cell susceptibility to CDDP-induced DNA damage and apoptosis.
• Elevated p-Chk1 and p-Chk2 expression indicated simultaneous activation of ATR-Chk1 and ATM-Chk2 DNA damage response pathways.

Conclusions:

• The combination of ML216 and CDDP exhibits synergistic anticancer effects in PCa.
• This combination strategy effectively targets DNA repair pathways, enhancing chemotherapy efficacy.
• ML216 and CDDP combination therapy represents a promising novel approach for prostate cancer treatment.